Literature DB >> 20738778

Increased PD-1 and decreased CD28 expression in chronic hepatitis B patients with advanced hepatocellular carcinoma.

Ping-Ning Hsu1, Tsuey-Ching Yang, Jung-Ta Kao, Ken-Sheng Cheng, Yi-Ju Lee, Yuan-Min Wang, Chin-Tung Hsieh, Cheng-Wen Lin, Yi-Ying Wu.   

Abstract

BACKGROUND/AIMS: Hepatitis B infection is a well-known cause of hepatocellular carcinoma (HCC). This study aims to investigate the role that the co-stimulatory molecule CD28 and co-inhibitory molecule programmed death-1 (PD-1) play in compromising the function of tumour-infiltrating lymphocytes (TIL) in hepatitis B virus (HBV)-related HCC.
METHODS: A total of 45 patients with HBV-related HCC were enrolled during the period February 2008 to March 2010. The immune phenotype and the expression of PD-1, CD28 and CD127 in TIL in biopsy specimens and in peripheral blood lymphocytes (PBL) from the same patients were analysed by flow cytometry.
RESULTS: Among the 45 patients, there was a male predominance (80%) and the mean age was 50 ± 13.68 years (range: 29-71). The majority of TIL were CD45RO(+) CD69(+). PD-1 expression was higher and CD28 and CD127 expression levels were lower in TIL than in PBL. The prevalence of portal vein thrombosis was 40%. Furthermore, tumour thrombosis invasion into the portal vein correlated with the expression level of the PD-1 co-inhibitory molecule.
CONCLUSION: PD-1(+) tumour-infiltrating lymphocytes correlate with portal vein thrombosis and might serve as a potential prognostic marker of and a novel therapeutic target for HBV-related HCC.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20738778     DOI: 10.1111/j.1478-3231.2010.02323.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  15 in total

1.  The co-inhibitory pathway and cellular immune imbalance in the progress of HBV infection.

Authors:  Jie Chen; Lanlan Wang; Yang Fu; Yi Li; Yangjuan Bai; Limei Luo; Yun Liao
Journal:  Hepatol Int       Date:  2013-08-27       Impact factor: 6.047

Review 2.  Immunobiology of hepatocellular carcinoma.

Authors:  Tobias Flecken; Hans Christian Spangenberg; Robert Thimme
Journal:  Langenbecks Arch Surg       Date:  2011-04-09       Impact factor: 3.445

3.  Utilizing gene expression profiles to characterize tumor infiltrating lymphocytes in cancers.

Authors:  Ching-Hsuan Chen; Tzu-Pin Lu
Journal:  Ann Transl Med       Date:  2019-12

4.  Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Bo Hong; Yun Qian; Hong Zhang; Yi-Wen Sang; Lin-Fang Cheng; Qi Wang; Song Gao; Min Zheng; Hang-Ping Yao
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

5.  Chronic hepatitis B: what should be the goal for new therapies?

Authors:  Timothy M Block; Robert Gish; Haitao Guo; Anand Mehta; Andrea Cuconati; W Thomas London; Ju-Tao Guo
Journal:  Antiviral Res       Date:  2013-02-04       Impact factor: 5.970

6.  PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model.

Authors:  Horng-Tay Tzeng; Hwei-Fang Tsai; Hsiu-Jung Liao; Yi-Jiun Lin; Lieping Chen; Pei-Jer Chen; Ping-Ning Hsu
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

7.  microRNA-4717 differentially interacts with its polymorphic target in the PD1 3' untranslated region: A mechanism for regulating PD-1 expression and function in HBV-associated liver diseases.

Authors:  Guoyu Zhang; Na Li; Zhu Li; Qianqian Zhu; Fang Li; Cuiling Yang; Qunying Han; Yi Lv; Zhihua Zhou; Zhengwen Liu
Journal:  Oncotarget       Date:  2015-08-07

8.  Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma.

Authors:  Zhu Li; Na Li; Fang Li; Zhihua Zhou; Jiao Sang; Yanping Chen; Qunying Han; Yi Lv; Zhengwen Liu
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

9.  Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection.

Authors:  Na Li; Zhihua Zhou; Fang Li; Jiao Sang; Qunying Han; Yi Lv; Wenxuan Zhao; Chunyan Li; Zhengwen Liu
Journal:  Oncotarget       Date:  2017-07-11

10.  Highly elevated soluble Tim-3 levels correlate with increased hepatocellular carcinoma risk and poor survival of hepatocellular carcinoma patients in chronic hepatitis B virus infection.

Authors:  Fang Li; Na Li; Jiao Sang; Xiude Fan; Huan Deng; Xiaoge Zhang; Qunying Han; Yi Lv; Zhengwen Liu
Journal:  Cancer Manag Res       Date:  2018-05-01       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.